Supplemental Table 3.2b. Transition Probabilities for Eligible Cohort From 4 to 7 Months. Transition probabilities for the 8 potential states in the Markov model, as measured among all eligible individuals in the retrospective CD cohort.

Tx in Month 4			Tx in Month 7							
Count Row Percent 95% CI	Total	Lost to Fup	0: No Meds	1: CS	2: IFX	3: ADA	4: CTZ	5: IFX + CS	6: ADA + CS	7: CTZ + CS
0: no meds	4222	296	2842	875	92	18	5	21	4	2
			72.4	22.3	2.3	0.5	0.1	0.5	0.1	0.1
			71.0-73.8	21.0-23.6	1.9-2.9	0.3-0.7	0.0-0.3	0.3-0.8	0.0-0.3	0.0-0.2
1: CS	3090	99	1242	1613	32	8	2	34	10	1
			41.5	53.9	1.1	0.3	0.1	1.1	0.3	0.0
			39.8-43.3	52.1-55.7	0.7-1.5	0.1-0.5	0.0-0.2	0.8-1.6	0.2-0.6	0.0-0.2
2: IFX	972	45	171	35	626	10	2	58	1	0
			18.4	3.8	67.5	1.1	0.2	6.3	0.1	0.0
			16.0-21.1	2.6-5.2	64.4-70.5	0.5-2.0	0.0-0.8	4.8-8.0	0.0-0.6	0.0-0.4
3: ADA	319	5	40	3	2	247	0	0	17	1

Tx in Month 4			Tx in Month 7							
Count Row Percent 95% CI	Total	Lost to Fup	0: No Meds	1: CS	2: IFX	3: ADA	4: CTZ	5: IFX + CS	6: ADA + CS	7: CTZ + CS
			12.7	1.0	0.6	78.7	0.0	0.0	5.4	0.3
			9.3-16.9	0.2-2.8	0.1-2.3	73.7-83.1	0.0-1.2	0.0-1.2	3.2-8.5	0.0-1.8
4: CTZ	81	1	9	1	1	2	54	1	0	10
			11.3	1.3	1.3	2.5	67.5	1.3	0.0	12.5
			5.3-20.3	0.0-6.8	0.0-6.8	0.3-8.7	56.1-77.6	0.0-6.8	0.0-4.5	6.2-21.8
5: IFX + CS	215	2	32	19	84	7	0	61	0	0
			15.0	8.9	39.4	3.3	0.0	28.6	0.0	0.0
			10.5-20.5	5.5-13.6	32.8-46.3	1.3-6.7	0.0-1.7	22.7-35.2	0.0-1.7	0.0-1.7
6: ADA + CS	86	3	10	3	0	40	1	0	23	1
			12.0	3.6	0.0	48.2	1.2	0.0	27.7	1.2
			5.9-21.0	0.8-10.2	0.0-4.3	37.1-59.4	0.0-6.5	0.0-4.3	18.4-38.6	0.0-6.5
7: CTZ + CS	14	0	1	3	0	0	4	0	0	6
			7.1	21.4	0.0	0.0	28.6	0.0	0.0	42.9
			0.2-33.9	4.7-50.8	0.0-23.2	0.0-23.2	8.4-58.1	0.0-23.2	0.0-23.2	17.7-71.1

ADA = Adalimumab; CS = corticosteroids; CTZ = Certolizumab; IFX = Infliximab; Tx = treatment. Gray shading denotes no change. Green shading denotes the most common transition when other than no change.